ClinicalTrials.gg
CompletedNCT05292859Updated Oct 15, 2026

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

An observational study in Gynecologic Cancer, Colorectal Cancer and Pancreatic Cancer, sponsored by Alaunos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Alaunos Therapeutics · Observational

How we know

Updated Oct 15, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
8
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
304th of 325
8 · median 220
Started
2022
with 126 others
Observational
326 of 2,342
68 open now
Registered
1,728th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 304th largest by enrollment of the 325 observational ones that give a count, is one of 127 that started in 2022, is one of 326 observational ones, and was the 1,728th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors

Read the detailed description

This is a prospective observational, non-interventional study for the long-term follow-up of safety and efficacy for subjects who have received autologous T cells engineered using the Sleeping Beauty System to express T cell receptors (TCRs) reactive against cancer-specific mutations (neoantigen specific TCR-T cells). In this study, subjects will be followed for up to 15 years after initial TCR-T cell drug product administration for evaluation of delayed adverse events (AEs).

Follow-up ended after 7 deaths were reported; 1 participant met the study criteria for lack of cell persistence. No participant remained in follow-up at the 06 July 2025 reporting cutoff.

03

Conditions studied

  • Gynecologic Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Non-small Cell Lung Cancer
  • Cholangiocarcinoma
  • Ovarian Cancer
  • Ovary Neoplasm
  • Squamous Cell Lung Cancer
  • Adenocarcinoma of Lung
  • Adenosquamous Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be enrolled following either the completion or early termination/discontinuation from Study NCT05194735 or any protocol in which patients were administered Neoantigen specific TCR-T cell drug product. Patients will begin the long-term follow-up period regardless of whether they responded to treatment or progressed on treatment. Patients will be followed for up to 15 years post TCR-T cell drug product infusion and will continue to be monitored for safety, immunogenicity and efficacy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects treated with TCR-T cell drug product on study TCR001-201 or any other Alaunos TCR-T cell drug product study and have either completed their original treatment protocol or have discontinued early.
  2. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  3. Subject must be capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  4. Subjects agree to allow clinical samples to be collected and stored at study site and/or Alaunos Therapeutics, Inc. (Alaunos) or designee for testing.

Exclusion criteria

Exclusion Criteria:

1. Subjects that were consented to this LTFU study but did not receive TCR-T cell drug product on study TCR001-201 will be excluded. No other exclusions are permitted.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Rollover subjects from Alaunos Therapeutics TCR-T cell drug product interventional studies

    This is a rollover protocol designed to provide long-term follow-up to all subjects previously enrolled in any Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product interventional studies. Patients will be followed for up to 15 years after dosing of Alaunos Therapeutics autologous, neoantigen specific TCR-T cell drug product.

    Biological: Neoantigen specific TCR-T cell drug product

Interventions

  • BiologicalNeoantigen specific TCR-T cell drug product

    No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy

06

What researchers measure

Primary outcomes

  1. To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells

    Incidence and duration of new related adverse events

    Time frame: Up to 2 years post TCR-T cell drug product infusion

  2. To assess the long-term safety of subjects that have received neoantigen-specific TCR-T cells

    * Incidence and duration of events of special interest, new Serious Adverse Events and new malignancies. * Incidence and duration of late onset adverse events * Proportion of subjects with adverse events leading to death * Incidence of subjects with resolution of adverse events/ serious adverse events and duration of events that began in study TCR001-201 or other clinical trial in which TCR-T cell drug product has been administered.

    Time frame: Up to 15 years post TCR-T cell drug product infusion

Secondary outcomes

  1. To investigate translational hypotheses related to TCR-T cell persistence.

    Duration of TCR-T cell drug product persistence by vector copy number (VCN).

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  2. To determine overall survival.

    Date of TCR-T cell drug product administration to death

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  3. To continue the clinical efficacy assessment of TCR-T cell product.

    Overall response by RECIST 1.1 for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  4. To continue the clinical efficacy assessment of TCR-T cell product.

    Overall response by iRECIST for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  5. To continue the clinical efficacy assessment of TCR-T cell product.

    Duration of response (DoR) for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  6. To continue the clinical efficacy assessment of TCR-T cell product.

    Progression-free survival (PFS) for subjects who did not have progressive disease on TCR001-201, proportion of subjects receiving subsequent curative therapies

    Time frame: Up to 15 years post TCR-T cell drug product infusion

Other outcomes

  1. To evaluate the long-term profile of persisting TCR-T cells.

    Primary and secondary malignancy: presence of TCR-T cells in tumor samples biopsy and autopsy.

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  2. To evaluate the long-term profile of persisting TCR-T cells.

    Determine the TCR-T persistence, defined by the duration of TCR-T cell drug product measurable by vector copy number (VCN) in peripheral blood samples

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  3. To evaluate the long-term profile of persisting TCR-T cells.

    Transposon insertion-site clonality in TCR-T cells over time.

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  4. To evaluate the long-term profile of persisting TCR-T cells.

    To evaluate changes in T cell infiltration that may occur within the tumor associated with disease progression following TCR-T cell infusion

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  5. To evaluate the long-term profile of persisting TCR-T cells.

    To evaluate infiltration of TCR-T cells within tumor tissue following disease progression

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  6. To evaluate the long-term profile of persisting TCR-T cells.

    To evaluate the presence of HLA alleles within the tumor associated with disease progression following TCR-T cell infusion

    Time frame: Up to 15 years post TCR-T cell drug product infusion

  7. To evaluate the long-term profile of persisting TCR-T cells.

    To evaluate changes in the presence of tumor-specific neoantigens within the tumor associated with disease progression following TCR-T cell infusion

    Time frame: Up to 15 years post TCR-T cell drug product infusion

07

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2025, 30 months.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 30 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Mar 2023 → Oct 2022, primary completion May 2025 → Apr 2025 and completion May 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2022
First posted
Mar 23, 2022
StartActual
Oct 7, 2022was Mar 2023
Primary completionActual
Apr 20, 2025was May 2025
CompletionActual
Apr 20, 2025was May 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2023→Oct 7, 2022
Oct 15, 2026
Primary completion
May 30, 2025→Apr 20, 2025
Oct 15, 2026
Study completion
May 30, 2025→Apr 20, 2025
Oct 15, 2026
Enrollment
7→8
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Mar 1, 2023→Oct 7, 2022
    Primary completion May 30, 2025→Apr 20, 2025
    Study completion May 30, 2025→Apr 20, 2025
    Enrollment 7→8
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05292859
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Oct 7, 2022
Primary completion
Apr 20, 2025
Completion
Apr 20, 2025
Last update
Oct 15, 2026

Study contacts

Scott Kopetz, MD, PhD
principal investigator · MD Anderson

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion